Cefiderocol for treating severe drug-resistant gram-negative bacterial infections

2.1 Under its contract with NHS England, the company will receive quarterly payments that are not linked to the volume of cefiderocol supplied to the NHS. The value of the payments was informed by the NICE committee's estimate of the benefits of cefiderocol, measured in quality-adjusted life years (QALYs) (see section 4.25 of the committee discussion). It has been agreed for a 3-year period, with an option to extend up to 10 years.

2.2 Purchasing authorities will acquire cefiderocol using an agreed confidential invoice price. NHS England will subtract the costs of these purchases from its quarterly payments to the company.

2.3 NHS organisations can find the confidential invoice price for cefiderocol in the NHS Pharmacy Catalogue. Non-NHS organisations can contact contact@shionogi.eu for details.

2.4 The contract between the company and NHS England also stipulates conditions relating to good antimicrobial stewardship, manufacturing and environmental practices; monitoring for emerging resistance; and ensuring supply of cefiderocol.